STUDIES IN MYASTHENIA GRAVIS: PRESENT STATUS OF THERAPY WITH OCTAMETHYL PYROPHOSPHORAMIDE (OMPA)
Authors: K E OSSERMAN, L I KAPLAN
Journal: Annals of Internal Medicine (1954)

Article1 July 1954STUDIES IN MYASTHENIA GRAVIS: PRESENT STATUS OF THERAPY WITH OCTAMETHYL PYROPHOSPHORAMIDE (OMPA)KERMIT E. OSSERMAN, M.D., F.A.C.P., LAWRENCE I. KAPLAN, M.D.KERMIT E. OSSERMAN, M.D., F.A.C.P.Search for more papers by this author, LAWRENCE I. KAPLAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-41-1-108 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn 1935 neostigmine1 was introduced as an agent for the treatment of myasthenia gravis. It is still the drug of choice but, because of the frequency of dosage and the development of refractoriness in some patients, there has been a concentrated search for another, more nearly ideal therapeutic agent.In recent years potent anticholinesterase (antiChE) drugs, the alkyl phosphates, were introduced for the treatment of myasthenia gravis. These include di-isopropyl fluorophosphate (DFP),2tetraethylpyrophosphate (TEPP),3and hexaethyltetraphosphate (HETP).4DFP was found to be a very effective antiChE agent, but toxic and not effective therapeutically. HETP and TEPP were found to be...Bibliography1. VietsSchwab HRRS: Prostigmine in the diagnosis of myasthenia gravis, New England J. Med. 213: 1280, 1935. CrossrefGoogle Scholar2. ComroeToddGammonLeopoldKoelleBodanskyGilman JHJGDIHGBOA: The effect of di-isopropyl fluorophosphate (DFP) upon patients with myasthenia gravis, Am. J. M. Sc. 212: 641 (Dec.) 1946. CrossrefMedlineGoogle Scholar3. GrobHarvey DAM: Observations on the effects of tetraethylpyrophosphate (TEPP) in man and on its use in the treatment of myasthenia gravis, Bull. Johns Hopkins Hosp. 84: 532 (June) 1949. MedlineGoogle Scholar4. WesterbergLures MRJT: The clinical use of hexaethyltetraphosphate in myasthenia gravis, Univ. Hosp. Bull., Ann Arbor 14: 15 (Feb.) 1948. MedlineGoogle Scholar5. RiderSchulmanRichterMoellerDuBois AJSRBHCKP: Treatment of myasthenia gravis with octamethylpyrophosphoramide, J. A. M. A. 145: 967 (Mar. 31) 1951. CrossrefMedlineGoogle Scholar6. GregoryFutchStone LEDCT: Octamethyl pyrophosphoramide in the therapy of myasthenia gravis, Am. J. Med. 13: 423 (Oct.) 1952. CrossrefMedlineGoogle Scholar7. Grob D: Course and management of myasthenia gravis, J. A. M. A. 153: 529 (Oct. 10) 1953. CrossrefMedlineGoogle Scholar8. WilsonWilliamsMiller CWJPDH: The hazard of cholinergic crisis during treatment of myasthenia gravis with octamethylpyrophosphoramide, Ann. Int. Med. 37: 574 (Sept.) 1952. LinkGoogle Scholar9. OssermanKaplanBesson KELIG: Studies in myasthenia gravis: edrophonium chloride (Tensilon) test as a new approach to management, J. Mt. Sinai Hosp. 20: 165 (Sept.-Oct.) 1953. MedlineGoogle Scholar10. OssermanKaplan KELI: Studies in myasthenia gravis: Use of edrophonium chloride (Tensilon) in differentiating myasthenic from cholinergic weakness, A. M. A. Arch. Neurol. and Psychiat. 70: 385 (Sept.) 1953. MedlineGoogle Scholar11. OssermanKaplan KELI: Rapid diagnostic test for myasthenia gravis: increased muscle strength, without fasciculations, after intravenous administration of edrophonium (Tensilon) chloride, J. A. M. A. 150: 265 (Sept. 27) 1952. CrossrefMedlineGoogle Scholar12. SchulmanRiderRichter SJARB: Use of octamethylpyrophosphoramide in the treatment of myasthenia gravis, J. A. M. A. 152: 1707 (Aug. 29) 1953. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication November 20, 1953.From The Myasthenia Gravis Clinic and The Departments of Medicine and Neurology, The Mount Sinai Hospital, New York, N. Y.The octamethyl pyrophosphoramide used in this study was supplied by Dr. C. G. Weigand, of the Eli Lilly Company.The edrophonium chloride used in this study was supplied by Dr. T. C. Fleming, of Hoffman-La Roche, Incorporated. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTherapy of Myasthenia GravisPharmacological Considerations in the Treatment of Myasthenia GravisTratamento das formas severas de miastenia pelo ACTH por via intravenosaMyasthenia gravisThe long-acting anticholinesterase drugs in the management of myasthenia gravis 1 July 1954Volume 41, Issue 1Page: 108-111KeywordsChloridesDrugsHospital medicineMyasthenia gravisNeurologyPhosphatesToxic agents ePublished: 1 December 2008 Issue Published: 1 July 1954 PDF downloadLoading ...